Title : Reversal of TGF-β-induced epithelial-mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor.

Pub. Date : 2021

PMID : 34909649






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Reversal of TGF-beta-induced epithelial-mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor. Sorafenib kinase insert domain receptor Homo sapiens
2 Sorafenib, a RAF kinase and VEGFR-2 inhibitor, exhibits efficacy against advanced hepatocellular carcinoma (HCC), renal carcinoma, and thyroid cancer. Sorafenib kinase insert domain receptor Homo sapiens